Cross-Sector entity
Butterfly Network is the most frequent co-covered peer, appearing in 4 of the 5 tracked stories. earnings accounts for 3 of the 5 tracked stories, while 2 other categories carry the remainder. Each carries 5.4 original sources on average. We currently track 5 Cross-Sector stories that mention Delcath Systems, all published on February 25, 2026.
5 verified stories tracked
Last mentioned: Feb 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Butterfly Network is the most frequent co-covered peer, appearing in 4 of the 5 tracked stories. earnings accounts for 3 of the 5 tracked stories, while 2 other categories carry the remainder. Each carries 5.4 original sources on average. We currently track 5 Cross-Sector stories that mention Delcath Systems, all published on February 25, 2026. Negative sentiment appears in 0% of the tracked stories.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Delcath Systems. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle highlights a critical juncture for apparel manufacturing and cross-border e-commerce. Gildan Activewear and Payoneer Global serve as key bellwethers for consumer demand and global trade efficiency.
Source: Seeking Alpha · Seeking Alpha
A wave of Q4 2025 earnings previews highlights the growing intersection of specialized SaaS platforms and high-stakes medical and infrastructure sectors. Companies like Delcath Systems and Bentley Systems are under scrutiny as investors look for evidence of commercial scaling and software-driven efficiency gains.
Source: Seeking Alpha · Seeking Alpha
As the Q4 2025 earnings season intensifies, four key players in the specialized medical technology and biotechnology sectors—Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings—are preparing to report results. Investors are focusing on commercial execution, product adoption rates, and the sustainability of high-growth specialized therapies.
As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.
Delcath Systems, Lantheus Holdings, Butterfly Network, and Heron Therapeutics are preparing to report Q4 2025 earnings, marking a critical test for commercial-stage medical innovators. Investors are laser-focused on the adoption rates of flagship products like HEPZATO KIT and PYLARIFY as these companies navigate a complex reimbursement environment.
Source: Seeking Alpha · Seeking Alpha
